TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore poster on its Phase 1 single-dose escalation study of TMB-365 Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore poster on its Phase 1 single-dose escalation study of TMB-365
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.